• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Dulera (mometasone furoate + formoterol fumarate dihydrate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Dulera (mometasone furoate + formoterol fumarate dihydrate)

  • Profile

Profile

Contact Information

Contact: Organon
Website: https://www.dulera.com/

Currently Enrolling Trials

    Show More

    General Information

    Dulera Inhalation Aerosal is a fixed-dose combination of the inhaled corticosteroid mometasone furoate plus the long-acting beta2-agonist formoterol fumarate dihydrate.

    Dulera is specifically indicated for the treatment of asthma in patients 12 years of age and older.

    Dulera is supplied as as an inhalation aerosal. The recommended starting dosages for Dulera treatment are based on prior asthma therapy. 

    Previous Therapy: Inhaled medium dose corticosteroids

    • Recommended Dose: 100 mcg/5 mcg, 2 inhalations twice daily
    • Maximum Recommended Daily Dose: 400 mcg/20 mcg

    Previous Therapy: Inhaled high dose corticosteroids

    • Recommended Dose: 200 mcg/5 mcg, 2 inhalations twice daily
    • Maximum Recommended Daily Dose: 800 mcg/20 mcg

    Mechanism of Action

    Dulera Inhalation Aerosal is a fixed-dose combination of the inhaled corticosteroid mometasone furoate plus the long-acting beta2-agonist formoterol fumarate dihydrate.

    Side Effects

    Adverse events associated with the use of Dulera may include, but are not limited to, the following:

    • Nasopharyngitis
    • Sinusitis
    • Headache

    Clinical Trial Results

    The FDA approval of Dulera was partially based on two randomized clinical trials (Trial 1, Trial 2). These trials enrolled a total of 1,509 patients 12 years of age and older with persistent asthma uncontrolled on medium or high dose inhaled corticosteroids. These studies included a 2 to 3-week run-in period with mometasone furoate to establish a certain level of asthma control. Trial 1 compared Dulera 100 mcg/5 mcg to its individual components, mometasone furoate 100 mcg and formoterol 5 mcg, and placebo). Trial 2 compared Dulera 200 mcg/5 mcg with Dulera 100 mcg/5 mcg and mometasone furoate 200 mcg. All medications were given as two inhalations twice daily by metered dose inhalers. In both trials Dulera resulted in significant improvement from baseline in lung function (mean area under the concentration-time curve for forced expiratory volume in 1 second, measured from 0 to 12 hours [FEV1 AUC0-12h]) at week 12, a primary efficacy endpoint, compared to mometasone furoate (Trial 1 and 2) and placebo (Trial 1). In Trial 1, these differences were maintained through week 26. The change in mean trough FEV1 from baseline to week 12 was assessed as another endpoint in both trials. In Trial 1, a significantly greater increase in the mean trough FEV1 was observed for Dulera 100 mcg/5 mcg compared to formoterol 5 mcg (the primary treatment comparison) as well as to placebo. In trial 2, a greater numerical increase in the mean trough FEV1 were was observed for Dulera 200 mcg/5 mcg compared to Dulera 100 mcg/5 mcg and mometasone furoate 200 mcg.

    Approval Date: 2010-06-01
    Company Name: Organon
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing